Focus On Unmet Medical NeedsTargeting unmet medical needs can lead to significant market opportunities if the company successfully develops effective treatments, particularly in aging-related conditions where demand is growing.

Lead Product CandidateA focused development on a lead product candidate can streamline resources and increase the likelihood of achieving regulatory approval, potentially unlocking revenue streams through commercialization.

Potential PartnershipsPotential partnerships and licensing agreements can provide crucial funding and resources, enhancing the company's ability to bring products to market and share risks with established players.

Bears Say

Persistent Financial LossesOngoing financial losses and negative equity indicate severe financial instability, which could hinder long-term operations and the ability to fund R&D activities necessary for future growth.

Negative Cash FlowNegative cash flow suggests the company is burning cash without generating sufficient operational income, which may necessitate further financing and dilute shareholder value.

Lack Of Revenue GrowthThe lack of revenue growth and high negative margins highlight severe profitability issues, questioning the company's ability to sustain operations and achieve financial stability.

Nymox Pharmaceutical News

Nymox Pharmaceutical Faces Challenges as NX-1207 Trials Fall Short

An announcement from Nymox Pharmaceutical ( ($NYMXF) ) is now available. Nymox Pharmaceutical announced that their Phase 3...

1y ago

Nymox resumes trading with listing on OTCQB

Nymox (NYMXF) Pharmaceutical Corporation announced that the Company’s stock has resumed trading under the symbol NYMXF on the...

1y ago

NYMXF

NYMXF FAQ

What was Nymox Pharmaceutical’s price range in the past 12 months?

Nymox Pharmaceutical lowest stock price was $0.03 and its highest was $0.15 in the past 12 months.

What is Nymox Pharmaceutical’s market cap?

Nymox Pharmaceutical’s market cap is $3.79M.

When is Nymox Pharmaceutical’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Nymox Pharmaceutical’s earnings last quarter?

Currently, no data Available

Is Nymox Pharmaceutical overvalued?

According to Wall Street analysts Nymox Pharmaceutical’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nymox Pharmaceutical pay dividends?

Nymox Pharmaceutical does not currently pay dividends.

What is Nymox Pharmaceutical’s EPS estimate?

Nymox Pharmaceutical’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nymox Pharmaceutical have?

Nymox Pharmaceutical has 94,540,140 shares outstanding.

What happened to Nymox Pharmaceutical’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nymox Pharmaceutical?

Currently, no hedge funds are holding shares in NYMXF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nymox Pharmaceutical

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.